JO
IMRX icon

John Overdeck’s Immuneering IMRX Stock Holding History

John Overdeck’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Buy
288,420
+43,649
+18% +$221K ﹤0.01% 3312
2026
Q1 		$1.29M Buy
244,771
+37,616
+18% +$193K ﹤0.01% 3062
2025
Q4 		$1.36M Buy
207,155
+99,284
+92% +$637K ﹤0.01% 2722
2025
Q3 		$755K Buy
107,871
+89,318
+481% +$464K ﹤0.01% 2762
2025
Q2 		$62.5K Sell
18,553
-17,204
-48% -$29.5K ﹤0.01% 3049
2025
Q1 		$54.4K Sell
35,757
-14,800
-29% -$26.9K ﹤0.01% 3037
2024
Q4 		$111K Buy
50,557
+10,126
+25% +$21K ﹤0.01% 2955
2024
Q3 		$101K Sell
40,431
-169,594
-81% -$247K ﹤0.01% 2898
2024
Q2 		$269K Buy
+210,025
New +$345K ﹤0.01% 2643
2022
Q3 		– Sell
-17,138
Closed -$93K – 2625
2022
Q2 		$93K Sell
17,138
-34,222
-67% -$183K ﹤0.01% 2276
2022
Q1 		$332K Buy
+51,360
New +$493K ﹤0.01% 2180

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

John Overdeck's IMRX Position: Q2 2026 in Review

John Overdeck increased its Immuneering (IMRX) stake by 18% in Q2 2026, buying an estimated $221K and bringing the position to 288,420 shares worth $1.44M. The position accounts for ﹤0.01% of the portfolio, ranked #3312.

John Overdeck first reported a position in IMRX in Q1 2022 and has held it in 11 quarters since. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • John Overdeck held 288,420 shares of Immuneering worth $1.44M as of Q2 2026.
  • John Overdeck bought 43,649 Immuneering shares in Q2 2026, an estimated $221K.
  • Immuneering made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3312 holding.
  • John Overdeck first reported a position in Immuneering in Q1 2022 and has held it in 11 quarters since.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.